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Effect of WhatsApp messaging based intervention on insulin adher-
ence and treatment effectiveness in diabetic patients in central India
S. Saboo, B. Saboo;
Diabetology, Prayas Diabetes Center, Indore, India.
Background and aims: Low adherence to pharmacological therapy and
monitoring by patients with diabetes mellitus is very common and repre-
sents a challenge. Technological Help has came to a rescue in connecting
with patients during this covid-19 period by enhancing communication
and the reach for the healthcare. WhatsApp is a very commonly used
social media app and its available with most of the patients. This study
examined the effect of an intervention using WhatsApp® messaging on
insulin adherence and treatment effectiveness in patients with diabetes
Materials and methods:A randomized clinical trial was performed with
573 patients who had diabetes and/or hypertension and who had enrolled
in a diabetes clinic. The patients were randomly assigned to either the
intervention group (n = 296), which received usual care plus WhatsApp
messages-based dose titration for insulin with an emphasis on medication
adherence, or the control group. The control group (n = 277) only
received usual care. Medication adherence, as measured by the
Morisky-Green Test, was compared after 32 weeks
Results: After the follow-up period (8 months), 78.5% of the patients in
the intervention group were adherent versus 57.2% in the control group.
Also, the number of patients achieving target hba1c <7% were more in
intervention group 73 % as compared to control group 52 %.
Conclusion: Diabetes is a progressive disease, and the treatment
should be continuous. Technological aids using WhatsApp could
be useful as a reinforcement to increase adherence to medication
and achieving target levels of optimum health. This approach is well
accepted by patients and easily accessible to them and it maintains
connection between patient and caregivers during and after covid-19
period. If used judiciously it can reduce the burden on our
healthcare system and yield better outcomes in terms of better treat-
ment adherence and treatment outcomes.
Disclosure: S. Saboo: None.
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Long-term HbA1c outcomes with and without intermittent CGM use
in adults with type 2 diabetes participating in the Onduo Program
J.E. Layne1, R.M. Bergenstal2, N.A. Barleen1, R.F. Dixon3, H. Zisser4;
1Onduo LLC, Newton, 2International Diabetes Center at Park Nicollet,
Minneapolis, 3Remedy, Needham, 4Verily Life Sciences, South San
Francisco, USA.
Background and aims: The Onduo Virtual Diabetes Clinic (VDC) for
people with type 2 diabetes (T2D) combines a mobile app, remote life-
style coaching and video consultations with board-certified endocrinolo-
gists for medication management and prescription of real-time (rt)CGM
devices for intermittent use in high risk participants. This analysis exam-
ined change in HbA1c at 6 months and 1 year in VDC participants with
and without intermittent rtCGM use.
Materials and methods: Adults ≥18 years of age with T2D who enrolled
in the VDC program from February 2018 through April 2019 with baseline
and follow-up HbA1c values at 1 year were included. The CGMgroup was
required to have used CGM ≥30 days prior to the follow-up HbA1c
measurement. Outcomes included within group change in mean HbA1c
with and without CGM use. Subgroup analysis was performed for partici-
pants with 6-month and 1-year data. Between group comparisons for
change in HbA1c stratified by baseline categories of >9.0%, 8.0 to 9.0%,
7.0 to <8.0%, <7.0% and by <8.0% and ≥8.0% were evaluated by a two-
sample t-test for equivalence of mean change in HbA1c between groups.
Results: Of the cohort (n=772), 45.9% (n=354) used CGM and 54.1%
(n=418) did not use CGM. At baseline the CGM group was significantly
younger (mean±SD): 53.3±8.6 vs 55.1±9.4 years, had higher HbA1c:
7.9%±1.8 vs 7.6%±1.7, and greater insulin use: 36.2% vs 28.5%.
Change in HbA1c at 1 year is presented in the Table. The increase in
participants meeting the Health Effectiveness Data and Information Set
(HEDIS) target of HbA1c <8.0% was greater in the CGM group, 55.1%
to 78.3%, vs no CGM, 60.8% to 74.0% (p=0.002). Subgroup analysis
(n=468, 60.6%) revealed significant improvement in HbA1c at 6 months
and 1 year for both the CGM and no CGM groups with a baseline HbA1c
>8.0% (p<0.001). On average participants meeting the American
Diabetes Association (ADA) treatment target of HbA1c <7.0% at base-
line remained at target at 6 months and 1 year.
Conclusion: Participation in the Onduo VDC was associated with a
significant reduction in HbA1c at 1 year in those not meeting treatment
targets, with approximately 2-fold greater improvement with CGM use.
These results suggest that improvement in HbA1c observed at 6 months
was maintained at 1 year.
Disclosure: J.E. Layne: Employment/Consultancy; Employee of
Onduo, LLC, the study Sponsor.
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Development of a new device for screening for peripheral diabetic
neuropathy
D. Coppini1,2, J. Dave3, V. Dubey3;
1Poole Hospital, Poole, UK, 2Mater Dei Hospital, Msida,
Malta, 3Bournemouth University, Bournemouth, UK.
Background and aims:We developed a new tool called 'Vibrascan' that
utilises a vibratory plate for the screening of peripheral diabetic neurop-
athy. Its design was based on the mechanics of the Neurothesiometer, but
is intended as a more intuitive, operator- independent testing instrument.
Materials and methods: Twenty healthy subjects were tested using both
Neurothesiometer and VibraScan. For using the Neurothesiometer, a
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single operator measured VPT (vibration perception thresholds in Volts
(V). VibraScan can be operated independently by the subject in the sitting
position and placing both feet on the vibrating plate. The range of vibra-
tion used is the same for both devices (i.e. from 0V to 50V). The frequen-
cy and amplitude of VibraScan is completely programmable such that
severity level can be interpreted automatically by the device. VPT
measurements by both devices were correlated using the Bland -
Altman method in order to measure the agreement between both devices.
Results: Mean VPT measured for left and right foot using Neurothesiometer
was 4.53 ± 0.65 Vand 4.97 ± 0.57 V, and 4.76 ± 0.60 Vand 5.22 ± 0.67 V for
left and right foot using VibraScan. There was very good correlation between
individual values for each device (r = 0.893, p < 0.01 for right foot and r =
0.816, p < 0.01 for left foot). Despite the differences in operation technique,
there was very little difference in VPT measurements between devices. when
using the using Bland-Altman method.
Conclusion: The intuitive, quick and essentially observer independent
nature of VibraScan enables an important new normal method of screen-
ing for the at risk foot in diabetic individuals. Further studies on diabetic
subjects with varying severity of neuropathy are planned to help strength-
en its possible role for screening patients in tandem with their annual eye
screening visit, a much awaited unified approach in the modern manage-
ment of diabetes.
Disclosure: D. Coppini: None.
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High treatment satisfaction and less severe hypoglycaemia after 24-
month use of intermittently scanned continuous glucose monitoring
S. Charleer1, C. De Block2, L. Van Huffel3, E. Dirinck2, F. Nobels3, C.
Mathieu1, P. Gillard1,4;
1University Hospitals Leuven - KU Leuven, Leuven, 2University
Hospital Antwerp, Edegem, 3OLV Hospital Aalst, Aalst, 4Research
Foundation Flanders (FWO), Brussels, Belgium.
Background and aims: Nationwide reimbursement of intermittently
scanned continuous glucose monitoring (isCGM) was introduced in
Belgium in 2016. This prospective observational multicentre real-world
trial (FUTURE) studies the impact of isCGM on quality of life (QOL)
and glycaemic control of people with type 1 diabetes (T1D) in 3 diabetes
centres. Here, we report the 24-month data of the FUTURE trial.
Materials and methods: Between July 2016 and July 2018, 1906 T1D
adults were consecutively recruited. Demographic, metabolic, glucose,
and QOL (SF-36, Problem Areas In Diabetes-Short Form,
Hypoglycaemia Fear Survey, Diabetes Treatment Satisfaction
Questionnaire [DTSQ]) data were collected at start, 6, 12, and 24 months
of standard follow-up. Primary endpoint was evolution of QOL.
Secondary endpoints were change in HbA1c, self-reported severe
hypoglycaemia and diabetes-related work absence, and number of people
who reach clinical CGM consensus targets. Data are mean±SD, least-
square mean (95% CI), or n (%).
Results: Of 1906 people who started isCGM, 1577 (83%) used isCGM
for at least 24 months. Twelve percent (n=237) discontinued isCGM due
to switching to real-time CGM (n=75; 32%), skin irritation or allergy
(n=39; 17%), and frequent sensor loss (n=26; 11%). People were 46±15
years old, had T1D for 23±14 years, 22% were using an insulin pump,
16% (n=299) were hypoglycaemia unaware, with HbA1c of 7.8±1.2%.
QOL scores were high at baseline and remained stable. DTSQ satisfaction
improved from 28.0 (26.1-29.8) to 30.4 (28.6-32.2) (p<0.0001), with
high self-reported treatment satisfaction (8.5±1.4 on a scale of 10).
HbA1c did not change over 24 months. Compared to 6 months before
isCGM initiation, fewer people experienced severe hypoglycaemic events
needing help from others (17.7% [n=314] vs 9.5% [n=150]; p<0.0001)
and hypoglycaemic comas (3.8% [n=67] vs 1.1% [n=18]; p<0.0001) in
the 6 months prior to the 24-month time point. The same evolution was
observed in number of severe hypoglycaemic events needing help from
others (83.1 vs 44.5 events/100 patient-years; p=0.003) and
hypoglycaemic comas (9.5 vs 3.0 events/100 patient-years; p=0.009).
Additionally, fewer people were absent from work (7.7% [n=134] vs
2.5% [n=39]; p<0.0001) and missed fewer days of work (80.8 vs 35.1
days/100 patient-years; p=0.009). From the first twoweeks of isCGM use
up to 24months, more people reached the targets of <4% of time <70mg/
dL (24.0% [n=331] vs 29.5% [n=367]; p<0.0001), >70% of time 70-180
mg/dL (10.4% [n=143] vs 12.0% [n=148]; p=0.046), <25% of time >180
mg/dL (18.5% [n=256] vs 20.1% [n=249]; p=0.025), and <5% of time
>250 mg/dL (15.4% [n=212] vs 20.6% [n=254]; p<0.0001). Results are
comparable when omitting drop-outs from analyses.
Conclusion: isCGM use over 24 months in a large T1D population
increases treatment satisfaction while maintaining other aspects of
QOL and HbA1c. The lower prevalence of people who experience
severe hypoglycaemia and who miss work, together with more
people who achieve the consensus targets for hypoglycaemia and
hyperglycaemia indicate that isCGM can be beneficial in long-
term diabetes care.
Clinical Trial Registration Number: NCT02898714
Disclosure: S. Charleer: None.
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